Shanghai Haohai Biological Technology Co., Ltd. provided preliminary unaudited consolidated group earnings guidance for the year ended 31 December 2023. For the year, the group expects to record a net profit attributable to shareholders of the Company of approximately RMB 400,000,000 to RMB 430,000,000, representing an increase of approximately RMB 219,530,300 to RMB 249,530,300, or approximately 121.64% to 138.27%, as compared to that in 2022 (corresponding period in 2022: audited net profit attributable to shareholders of the Company of RMB 180,469,733.31). The net profit attributable to shareholders of the Company after deducting the non-recurring profit or loss is expected to be approximately RMB 367,000,000 to RMB 397,000,000, representing an increase of approximately RMB 208,250,400 to RMB 238,250,400, or approximately 131.18% to 150.08%, as compared to that in 2022 (corresponding period in 2022: audited net profit attributable to shareholders of the Company after deducting the non-recurring profit or loss of RMB 158,749,648.52).
Shanghai Haohai Biological Technology Co., Ltd.
Equities
6826
CNE100001W69
Medical Equipment, Supplies & Distribution
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
42.35 HKD | +0.83% | +3.42% | +5.09% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+5.09% | 1.99B | |
-3.79% | 184B | |
-0.84% | 108B | |
-3.75% | 67.8B | |
+3.45% | 51.05B | |
+9.04% | 44.67B | |
+3.40% | 41.78B | |
+3.66% | 26.59B | |
+3.21% | 26.78B | |
+15.23% | 25.86B |
- Stock Market
- Equities
- 6826 Stock
- News Shanghai Haohai Biological Technology Co., Ltd.
- Shanghai Haohai Biological Technology Co., Ltd. Provides Preliminary Unaudited Consolidated Group Earnings Guidance for the Year Ended 31 December 2023